RU2653497C2 - Производные пантотената для лечения неврологических заболеваний - Google Patents

Производные пантотената для лечения неврологических заболеваний Download PDF

Info

Publication number
RU2653497C2
RU2653497C2 RU2014147739A RU2014147739A RU2653497C2 RU 2653497 C2 RU2653497 C2 RU 2653497C2 RU 2014147739 A RU2014147739 A RU 2014147739A RU 2014147739 A RU2014147739 A RU 2014147739A RU 2653497 C2 RU2653497 C2 RU 2653497C2
Authority
RU
Russia
Prior art keywords
subject
compound
substituted
unsubstituted
treating
Prior art date
Application number
RU2014147739A
Other languages
English (en)
Russian (ru)
Other versions
RU2014147739A (ru
Inventor
Эндрю ВАЙНО
Марек БИЕСТЕК
Мартин ШКРЕЛИ
Original Assignee
Ретрофин, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ретрофин, Инк. filed Critical Ретрофин, Инк.
Publication of RU2014147739A publication Critical patent/RU2014147739A/ru
Application granted granted Critical
Publication of RU2653497C2 publication Critical patent/RU2653497C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014147739A 2012-04-27 2013-04-26 Производные пантотената для лечения неврологических заболеваний RU2653497C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639602P 2012-04-27 2012-04-27
US61/639,602 2012-04-27
PCT/US2013/038458 WO2013163576A1 (en) 2012-04-27 2013-04-26 Pantothenate derivatives for the treatment of neurologic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018112720A Division RU2018112720A (ru) 2012-04-27 2013-04-26 Производные пантотената для лечения неврологических заболеваний

Publications (2)

Publication Number Publication Date
RU2014147739A RU2014147739A (ru) 2016-06-20
RU2653497C2 true RU2653497C2 (ru) 2018-05-10

Family

ID=48428654

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014147739A RU2653497C2 (ru) 2012-04-27 2013-04-26 Производные пантотената для лечения неврологических заболеваний
RU2018112720A RU2018112720A (ru) 2012-04-27 2013-04-26 Производные пантотената для лечения неврологических заболеваний

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2018112720A RU2018112720A (ru) 2012-04-27 2013-04-26 Производные пантотената для лечения неврологических заболеваний

Country Status (24)

Country Link
US (3) US8673883B2 (enExample)
EP (3) EP3112372B1 (enExample)
JP (3) JP6254151B2 (enExample)
KR (1) KR20150035550A (enExample)
CN (2) CN106977544B (enExample)
AU (3) AU2013251345B2 (enExample)
BR (1) BR112014026817A2 (enExample)
CA (1) CA2879314A1 (enExample)
CY (2) CY1118198T1 (enExample)
DK (2) DK2841438T3 (enExample)
ES (2) ES2708813T3 (enExample)
HR (2) HRP20161389T1 (enExample)
HU (2) HUE042199T2 (enExample)
IN (1) IN2014DN09584A (enExample)
LT (2) LT3112372T (enExample)
MX (1) MX360149B (enExample)
PL (2) PL3112372T3 (enExample)
PT (2) PT3112372T (enExample)
RS (2) RS55319B1 (enExample)
RU (2) RU2653497C2 (enExample)
SI (2) SI3112372T1 (enExample)
SM (2) SMT201900007T1 (enExample)
TR (1) TR201819263T4 (enExample)
WO (1) WO2013163576A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3112372T1 (sl) * 2012-04-27 2019-04-30 Retrophin, Inc. Derivati pantotenata za zdravljenje nevroloških motenj
US9896464B2 (en) 2013-10-25 2018-02-20 Retrophin, Inc. Pantothenate derivatives for the treatment of neurological disorders
EP2868662A1 (en) 2013-11-04 2015-05-06 Acies Bio d.o.o. Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
EP3386995A1 (en) * 2015-12-08 2018-10-17 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders
MX2019009342A (es) * 2017-02-07 2019-10-02 Retrophin Inc Formulaciones de fosmetpantotenato solido.
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002110463A (ru) * 1999-09-21 2004-02-27 Басф Акциенгезелльшафт (De) Способ и микроорганизмы для получения пантосоединений

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676976A (en) 1950-12-04 1954-04-27 Nat Res Dev Synthesis of pantothenic acid-4' phosphate
US2870188A (en) 1955-10-03 1959-01-20 Hoffmann La Roche Process for the manufacture of pantothenic acid 4'-phosphate and its salts
AU2002326412A1 (en) 2001-07-20 2003-03-03 Oregon Health And Science University Novel human nucleic acids encoding a pantothenate kinase and methods of use
US20060099692A1 (en) * 2002-07-03 2006-05-11 Yocum R R Microorganisms and processes for enhanced production of pantothenate
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
SI3112372T1 (sl) * 2012-04-27 2019-04-30 Retrophin, Inc. Derivati pantotenata za zdravljenje nevroloških motenj

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002110463A (ru) * 1999-09-21 2004-02-27 Басф Акциенгезелльшафт (De) Способ и микроорганизмы для получения пантосоединений

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.J. Balibar et al, Journal of Bacteriology, 2011, vol. 193, N13, 3304-3312. Scott J. Hecker et al, Journal of medicinal chemistry, American chemical society, 2008, vol. 51, N8, 2328-2345. Yousang Hwang et al, Bioorganic & Medicinal Chemistry, 2007, vol. 15, N5, 2147-2155. *
Hayflick Susan J. et al, Current opinion in pediatrics, 2003, vol. 15, N6, p. 572-577. *
Hayflick Susan J. et al, Current opinion in pediatrics, 2003, vol. 15, N6, p. 572-577. C.J. Balibar et al, Journal of Bacteriology, 2011, vol. 193, N13, 3304-3312. Scott J. Hecker et al, Journal of medicinal chemistry, American chemical society, 2008, vol. 51, N8, 2328-2345. Yousang Hwang et al, Bioorganic & Medicinal Chemistry, 2007, vol. 15, N5, 2147-2155. *

Also Published As

Publication number Publication date
HRP20161389T1 (hr) 2016-12-02
CN104520307A (zh) 2015-04-15
US20160015727A1 (en) 2016-01-21
RS58336B1 (sr) 2019-03-29
SMT201900007T1 (it) 2019-02-28
RU2014147739A (ru) 2016-06-20
LT2841438T (lt) 2016-11-10
KR20150035550A (ko) 2015-04-06
CN106977544B (zh) 2019-06-07
CA2879314A1 (en) 2013-10-31
AU2017239508C1 (en) 2019-11-07
DK3112372T3 (en) 2019-02-18
US9181286B2 (en) 2015-11-10
AU2013251345B2 (en) 2017-08-31
MX360149B (es) 2018-10-24
RU2018112720A (ru) 2019-02-28
SI2841438T1 (sl) 2016-12-30
EP2841438B1 (en) 2016-08-10
CY1121238T1 (el) 2020-05-29
PT3112372T (pt) 2019-01-17
DK2841438T3 (en) 2016-11-28
EP3489248A1 (en) 2019-05-29
JP2019206553A (ja) 2019-12-05
TR201819263T4 (tr) 2019-01-21
US20130289001A1 (en) 2013-10-31
CY1118198T1 (el) 2017-06-28
JP6560284B2 (ja) 2019-08-14
US20140135294A1 (en) 2014-05-15
JP2015515496A (ja) 2015-05-28
AU2017239508B9 (en) 2019-06-13
ES2600179T3 (es) 2017-02-07
JP6254151B2 (ja) 2017-12-27
US8673883B2 (en) 2014-03-18
MX2014013048A (es) 2015-04-10
US9629862B2 (en) 2017-04-25
RS55319B1 (sr) 2017-03-31
WO2013163576A1 (en) 2013-10-31
EP3112372A1 (en) 2017-01-04
ES2708813T3 (es) 2019-04-11
AU2017239508B2 (en) 2019-05-23
HUE042199T2 (hu) 2019-06-28
IN2014DN09584A (enExample) 2015-07-17
CN104520307B (zh) 2016-12-21
HK1207863A1 (en) 2016-02-12
AU2017239508A1 (en) 2017-10-26
AU2013251345A1 (en) 2014-11-27
BR112014026817A2 (pt) 2017-07-18
SI3112372T1 (sl) 2019-04-30
PT2841438T (pt) 2016-11-22
AU2019219733A1 (en) 2019-09-05
PL3112372T3 (pl) 2019-05-31
CN106977544A (zh) 2017-07-25
LT3112372T (lt) 2019-01-10
JP2017141257A (ja) 2017-08-17
HUE029474T2 (en) 2017-02-28
PL2841438T3 (pl) 2017-08-31
EP2841438A1 (en) 2015-03-04
HRP20190038T1 (hr) 2019-02-22
SMT201600395B (it) 2017-01-10
EP3112372B1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
AU2017239508B2 (en) Pantothenate derivatives for the treatment of neurologic disorders
US10407447B2 (en) Pantothenate derivatives for the treatment of neurological disorders
JP6568536B2 (ja) パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法
EP1165089A1 (fr) Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
AU2017301488A1 (en) Pantetheine derivatives for the treatment of neurologic disorders
HK1232544A1 (en) Pantothenate derivatives for the treatment of neurologic disorders
HK1207863B (en) Pantothenate derivatives for the treatment of neurologic disorders
HK1232544B (en) Pantothenate derivatives for the treatment of neurologic disorders

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200427